Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director | June 06, 2017 | June 13, 2017 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 06, 2017 · Filed June 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,921 |
Reported balance
After 2017-06-06 transaction · row 1
1 source rowRow 1 · 2017-06-06 · Exercise / conversion · Acquired 10,133 · Balance 18,921 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-06 · Exercise / conversion · Disposed 10,133 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,853 |
Reported balance
After 2017-06-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-07 · Grant · Acquired 15,853 · Balance 15,853 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. |
| Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2027-06-06 | Direct | 38,005 |
Reported balance
After 2017-06-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-07 · Grant · Acquired 38,005 · Balance 38,005 F3: Not applicable. F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.
F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.
F3: Not applicable.
F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
Jazz Pharmaceuticals plc
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 345,875 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 6,000 · Balance 345,875 F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2032-03-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 183,434 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $230.33 | $1,381,980.00 |
DisclosureSEC source: 0001193210-26-000028 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,875 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $250.13 | $1,500,780.00 |
DisclosureSEC source: 0001193210-26-000025 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,875 F3 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,209 | $241.39 | $291,840.39 |
DisclosureSEC source: 0001193210-26-000025 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 357,875 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 10 | $244.06 | $2,440.64 |
DisclosureSEC source: 0001193210-26-000025 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 359,084 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Includes the November 3, 2025 disposition of 3,193 shares for the withholding of restricted stock units by the Issuer to satisfy FICA taxes arising from the Reporting Person being retirement eligible which was previously inadvertently not reported; not an open market transaction. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001193210-26-000020 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,287 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $252.98 | $1,517,880.00 |
DisclosureSEC source: 0001193210-26-000018 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 360,682 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $240.47 | $1,442,820.00 |
DisclosureSEC source: 0001193210-26-000016 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 366,682 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $235.12 | $1,410,720.00 |
DisclosureSEC source: 0001193210-26-000013 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,682 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $203.33 | $1,219,980.00 |
DisclosureSEC source: 0001193210-26-000011 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,682 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 24 | $191.74 | $4,601.87 |
DisclosureSEC source: 0001193210-26-000009 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,682 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,292 | $190.94 | $437,630.58 |
DisclosureSEC source: 0001193210-26-000009 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,706 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.6051 to $190.5982. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,684 | $190.22 | $700,777.85 |
DisclosureSEC source: 0001193210-26-000009 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 386,998 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.60 to $190.5603. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 15,114 | $188.69 | $2,851,860.66 |
DisclosureSEC source: 0001193210-26-000007 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,682 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 233 | $187.84 | $43,767.75 |
DisclosureSEC source: 0001193210-26-000005 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,796 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $187.7783 to $188.1678 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,608 | $186.73 | $487,002.27 |
DisclosureSEC source: 0001193210-26-000005 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 406,029 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.500 to $187.4693. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,159 | $186.09 | $587,843.46 |
DisclosureSEC source: 0001193210-26-000005 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,637 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 17,453 | $171.16 | $2,987,255.48 |
DisclosureSEC source: 0001193210-26-000002 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,796 F2 · kind: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 35,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001193210-26-000002 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,249 F1 · kind: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 76,689 | $0.00 Strike: $123.36 | $0.00 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · derivative · entry 8 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 76,689 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 811 | $0.00 Strike: $123.36 | $0.00 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · derivative · entry 7 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 811 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 38,126 | $177.27 | $6,758,672.27 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · nonDerivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,332 F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.70 to $177.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 507 | $179.79 | $91,154.70 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,458 F3 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $179.73 to $179.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 8,380 | $179.23 | $1,501,943.21 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,965 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.72 to $179.705. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 30,487 | $178.06 | $5,428,567.05 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,345 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 811 | $123.36 | $100,044.96 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 76,689 | $123.36 | $9,460,355.04 |
DisclosureSEC source: 0001193210-25-000011 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 01:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001193210-25-000009 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,332 F5 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 01:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 717 | $182.60 | $130,924.85 |
DisclosureSEC source: 0001193210-25-000009 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,826 F4 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $181.59 to $182.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 01:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,517 | $181.81 | $1,003,071.15 |
DisclosureSEC source: 0001193210-25-000009 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,543 F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $181.41 to $182.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 01:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 8,382 | $180.88 | $1,516,131.13 |
DisclosureSEC source: 0001193210-25-000009 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,060 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $180.4028 to $181.385. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 01:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,384 | $180.09 | $609,410.69 |
DisclosureSEC source: 0001193210-25-000009 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,442 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.4013 to $180.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| October 03, 2025 Filed Oct 4, 2025 01:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,500 | $140.00 | $490,000.00 |
DisclosureSEC source: 0001193210-25-000007 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,826 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 01:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,000 | $131.78 | $263,560.00 |
DisclosureSEC source: 0001193210-25-000007 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,326 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 14, 2025 Filed Sep 17, 2025 21:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 15,647 | $126.16 | $1,974,025.52 |
DisclosureSEC source: 0001193210-25-000005 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,326 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,000 | $130.00 | $390,000.00 |
DisclosureSEC source: 0001765581-25-000098 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 429,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,000 | $127.23 | $381,690.00 |
DisclosureSEC source: 0001765581-25-000098 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $113.21 | $113,210.00 |
DisclosureSEC source: 0001765581-25-000049 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 18:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $110.00 | $55,000.00 |
DisclosureSEC source: 0001765581-25-000046 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 18:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $105.26 | $52,630.00 |
DisclosureSEC source: 0001765581-25-000046 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 437,473 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $110.00 | $55,000.00 |
DisclosureSEC source: 0001765581-25-000044 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 437,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $107.90 | $53,950.00 |
DisclosureSEC source: 0001765581-25-000044 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 438,473 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 92,158 | Not disclosed Strike: $4.46 | Not disclosed |
DisclosureSEC source: 0001962918-25-000066 · wk-form4_1748031058.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,158 shares Expires 2034-06-06 F2 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 23,243 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001962918-25-000066 · wk-form4_1748031058.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,243 shares Expires 2033-05-03 F2 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 183,434 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001962918-25-000066 · wk-form4_1748031058.xml · derivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 183,434 shares Expires 2032-03-07 F2 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1 · derivative.exercise_date: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 02, 2025 Filed May 5, 2025 23:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 500 | $120.00 | $60,000.00 |
DisclosureSEC source: 0001765581-25-000039 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 438,807 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $116.35 | $116,350.00 |
DisclosureSEC source: 0001765581-25-000039 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,307 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $123.75 | $185,625.00 |
DisclosureSEC source: 0001765581-25-000037 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,307 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 23:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 22,251 | $138.95 | $3,091,776.45 |
DisclosureSEC source: 0001765581-25-000024 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,807 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 00:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,500 | $144.25 | $937,625.00 |
DisclosureSEC source: 0001765581-25-000006 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,058 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 30,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000006 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 470,558 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on March 5, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.